Your browser doesn't support javascript.
loading
The cost associated with the development of the antimicrobial stewardship program in the adult general medicine setting in Qatar.
Abushanab, Dina; Al-Marridi, Wafa; Al Hail, Moza; Abdul Rouf, Palli Valappila; ElKassem, Wessam; Thomas, Binny; Alsoub, Hussam; Ademi, Zanfina; Hanssens, Yolande; Enany, Rasha El; Al-Badriyeh, Daoud.
Afiliação
  • Abushanab D; Department of Pharmacy, Hamad Medical Corporation, Doha, Qatar.
  • Al-Marridi W; College of Medicine, QU Health, Qatar University, Doha, Qatar.
  • Al Hail M; Department of Pharmacy, Hamad Medical Corporation, Doha, Qatar.
  • Abdul Rouf PV; Department of Pharmacy, Hamad Medical Corporation, Doha, Qatar.
  • ElKassem W; Department of Pharmacy, Hamad Medical Corporation, Doha, Qatar.
  • Thomas B; Department of Pharmacy, Hamad Medical Corporation, Doha, Qatar.
  • Alsoub H; Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
  • Ademi Z; Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia.
  • Hanssens Y; Department of Pharmacy, Hamad Medical Corporation, Doha, Qatar.
  • Enany RE; Department of Pharmacy, Hamad Medical Corporation, Doha, Qatar.
  • Al-Badriyeh D; College of Pharmacy, QU Health, Qatar University, Doha, Qatar.
J Pharm Policy Pract ; 17(1): 2326382, 2024.
Article em En | MEDLINE | ID: mdl-38549684
ABSTRACT

Objective:

To estimate the economic impact of the developed antimicrobial stewardship program (ASP) versus the preliminary ASP use, in the adults' general medicine settings in Qatar.

Methods:

Patient records were retrospectively reviewed during two periods preliminary ASP was defined as the 12 months following ASP implementation (i.e. May 2015-April 2016), and developed ASP was defined as the last 12 months of a 5-year ASP implementation in Hamad Medical Corporation (HMC) (i.e. February 2019-January 2020). The economic impact was the overall cost savings in resource use, including operational costs, plus the cost avoidance associated with ASP.

Results:

A total of 500 patients were included in the study. The operational costs decreased with the developed ASP. Whereas antimicrobial consumption and resource utilisation, and their associated costs, appear to have declined with the developed ASP, with a cost saving of QAR458 (US$125) per 100-patient beds, the avoided cost was negative, by QAR4,807 (US$1,317) per 100-patient beds, adding to a total QAR4,224 (US$1,160) increase in the 100-patient beds cost after ASP development.

Conclusions:

Despite that the developed ASP attained a total cost saving QAR458 (US$125) per 100-patient beds, the avoided cost was QAR-4,807 (US$-1,317) per 100-patient beds, which exceeded the cost savings achieved.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 Problema de saúde: 1_financiamento_saude Idioma: En Revista: J Pharm Policy Pract Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Qatar

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 Problema de saúde: 1_financiamento_saude Idioma: En Revista: J Pharm Policy Pract Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Qatar
...